Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01861301 · OUTCOME

Overall Survival

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma · Source last updated 2016-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 2 years

What was measured

Analyzed using the Kaplan-Meier method.

Groups in this outcome

Treatment (Tivantinib)

Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Tivantinib)18

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Tivantinib)12.2Not reported7.122.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7.1
        upper Limit
        22.2
        value
        12.2
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Analyzed using the Kaplan-Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Tivantinib)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 2 years
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice